



SARS-CoV-2 Serology for the Rapid Diagnosis of COVID-19

Guest Editor:

Dr. Jesus Alberto Silvas

U.S. Army Reserves, Aurora, CO
80045, USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Serological tests also vary according to the viral antigens measured. Spike proteins (S) and nucleocapsid proteins (N) are the viral antigens used to detect antibodies for SARS-CoV-2, with the intended use to identify whether an individual was recently or previously infected by the virus. These serology tests can be broadly categorized by their readout platforms used to detect SARS-CoV-2 antibodies: enzyme immunoassay, high-throughput; enzyme immunoassay, medium-throughput; lateral flow assay; and total neutralizing antibodies.

A reliable serology test to rapidly quantify neutralizing antibody levels in a high-throughput manner is essential for diagnosis, vaccine development, and antiviral development—especially once a minimal threshold of nAb has been defined for disease prevention in the near future. Even in a postvaccination era, serology tests will remain critical for studying both individuals' and the community's protective immunity to safeguard public health around the world. We would like to invite you to contribute with an original report, original observation, or review to highlight the new trends in serology tests for COVID-19.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)